Anders Bertelsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anders Bertelsen has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Carsten Brink
Laboratory of Radiation Physics, Odense University Hospital, Odense, Denmark
2 shared publications - Faisal Mahmood
Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Laboratory of Radiation Physics, Department of Oncology, Odense University Hospital, Odense, Denmark
2 shared publications Tine Schytte
Department of Clinical Research, University of Southern Denmark, Odense, Denmark
2 shared publications- Uffe Bernchou
Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Laboratory of Radiation Physics, Department of Oncology, Odense University Hospital, Odense, Denmark
2 shared publications Carsten Brink
Laboratory of Radiation Physics, Department of Oncology, Odense University Hospital, Odense, DENMARK
1 shared publicationDean B. Odwyer
Laboratory of Radiation Physics, Odense University Hospital , Odense , Denmark
1 shared publication
Latest Publications
- Open Access
- 15 September 2023
- Published by Elsevier in Physica Medica
- Vol. 114, 102682
Impact of abdominal compression on intra-fractional motion and delivered dose in magnetic resonance image-guided adaptive radiation ablation of adrenal gland metastases
- 15 September 2023
- Published by Elsevier in Physica Medica
- Vol. 114, 102682
Open AccessImpact of abdominal compression on intra-fractional motion and delivered dose in magnetic resonance image-guided adaptive radiation ablation of adrenal gland metastases
- Open Access
- 15 November 2022
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 24, 167-172
The effect of respiration-induced target motion on 3D magnetic resonance images used to guide radiotherapy
- 15 November 2022
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 24, 167-172
Open AccessThe effect of respiration-induced target motion on 3D magnetic resonance images used to guide radiotherapy
- 26 June 2019
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 58 (10) , 1352-1357
First clinical experiences with a high field 1.5 T MR linac
Purpose: A 1.5 T MR Linac (MRL) has recently become available. MRL treatment workflows (WF) include online plan adaptation based on daily MR images (MRI). This study reports initial clinical experiences after five months of use in terms of patient compliance, cases, WF timings, and dosimetric accuracy. Method and materials: Two different WF were used dependent on the clinical situation of the day; Adapt To Position WF (ATP) where the reference plan position is adjusted rigidly to match the position of the targets and the OARs, and Adapt To Shape WF (ATS), where a new plan is created to match the anatomy of the day, using deformable image registration. Both WFs included three 3D MRI scans for plan adaptation, verification before beam on, and validation during IMRT delivery. Patient compliance and WF timings were recorded. Accuracy in dose delivery was assessed using a cylindrical diode phantom. Results: Nineteen patients have completed their treatment receiving a total of 176 fractions. Cases vary from prostate treatments (60Gy/20F) to SBRT treatments of lymph nodes (45 Gy/3F) and castration by ovarian irradiation (15 Gy/3F). The median session time (patient in to patient out) for 127 ATPs was 26 (21–78) min, four fractions lasted more than 45 min due to additional plan adaptation. For the 49 ATSs a median time of 12 (1–24) min was used for contouring resulting in a total median session time of 42 (29–91) min. Three SBRT fractions lasted more than an hour. The time on the MRL couch was well tolerated by the patients. The median gamma pass rate (2 mm,2% global max) for the adapted plans was 99.2 (93.4–100)%, showing good agreement between planned and delivered dose. Conclusion: MRL treatments, including daily MRIs, plan adaptation, and accurate dose delivery, are possible within a clinically acceptable timeframe and well tolerated by the patients.
- 26 June 2019
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 58 (10) , 1352-1357
First clinical experiences with a high field 1.5 T MR linac
Purpose: A 1.5 T MR Linac (MRL) has recently become available. MRL treatment workflows (WF) include online plan adaptation based on daily MR images (MRI). This study reports initial clinical experiences after five months of use in terms of patient compliance, cases, WF timings, and dosimetric accuracy. Method and materials: Two different WF were used dependent on the clinical situation of the day; Adapt To Position WF (ATP) where the reference plan position is adjusted rigidly to match the position of the targets and the OARs, and Adapt To Shape WF (ATS), where a new plan is created to match the anatomy of the day, using deformable image registration. Both WFs included three 3D MRI scans for plan adaptation, verification before beam on, and validation during IMRT delivery. Patient compliance and WF timings were recorded. Accuracy in dose delivery was assessed using a cylindrical diode phantom. Results: Nineteen patients have completed their treatment receiving a total of 176 fractions. Cases vary from prostate treatments (60Gy/20F) to SBRT treatments of lymph nodes (45 Gy/3F) and castration by ovarian irradiation (15 Gy/3F). The median session time (patient in to patient out) for 127 ATPs was 26 (21–78) min, four fractions lasted more than 45 min due to additional plan adaptation. For the 49 ATSs a median time of 12 (1–24) min was used for contouring resulting in a total median session time of 42 (29–91) min. Three SBRT fractions lasted more than an hour. The time on the MRL couch was well tolerated by the patients. The median gamma pass rate (2 mm,2% global max) for the adapted plans was 99.2 (93.4–100)%, showing good agreement between planned and delivered dose. Conclusion: MRL treatments, including daily MRIs, plan adaptation, and accurate dose delivery, are possible within a clinically acceptable timeframe and well tolerated by the patients.